XML 51 R39.htm IDEA: XBRL DOCUMENT
v3.21.2

Derivative Financial Instruments - Warrants (Details) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended |
--- | --- | --- | ---
Jun. 30, 2021 USD ($) $ / shares shares | Jun. 30, 2020 USD ($) | Jun. 30, 2021 USD ($) $ / shares shares | Jun. 30, 2020 USD ($) | Dec. 31, 2020 $ / shares
Changes in the Company's derivative financial instruments liability balance |  |  |  |  |
Balance of warrants outstanding at the beginning of the period (in shares) | shares |  |  | 5,260,992 |  |
Balance of warrants outstanding at the end of the period (in shares) | shares | 4,490,159 |  | 4,490,159 |  |
Balance of derivative financial instruments liability at the beginning of the period |  |  | $ 285 |  |
Change in fair value of derivative financial instruments—warrants during the period recognized as a gain in the condensed statements of operations | $ 61 | $ (44) | 268 | $ (42) |
Balance of derivative financial instruments liability at the end of the period | $ 17 |  | $ 17 |  |
Warrants to purchase Common Stock |  |  |  |  |
Range of assumptions used to determine the fair value of warrants |  |  |  |  |
Estimated fair value of Cardiff Oncology common stock (in dollars per share) | $ / shares | $ 6.65 |  | $ 6.65 |  | $ 17.99
Warrants to purchase Common Stock | Black Scholes Option Pricing Method |  |  |  |  |
Changes in the Company's derivative financial instruments liability balance |  |  |  |  |
Balance of warrants outstanding at the beginning of the period (in shares) | shares |  |  | 64,496 |  |
Balance of warrants outstanding at the end of the period (in shares) | shares | 64,496 |  | 64,496 |  |
Balance of derivative financial instruments liability at the beginning of the period |  |  | $ 285 |  |
Change in fair value of derivative financial instruments—warrants during the period recognized as a gain in the condensed statements of operations |  |  | (268) |  |
Balance of derivative financial instruments liability at the end of the period | $ 17 |  | $ 17 |  |
Expected warrant term | Warrants to purchase Common Stock |  |  |  |  |
Range of assumptions used to determine the fair value of warrants |  |  |  |  |
Expected warrant term | 1 year 7 months 6 days |  | 1 year 7 months 6 days |  | 2 years 1 month 6 days
Risk-free interest rate | Warrants to purchase Common Stock |  |  |  |  |
Range of assumptions used to determine the fair value of warrants |  |  |  |  |
Measurement input | 0.0016 |  | 0.0016 |  | 0.0013
Expected volatility of Cardiff Oncology common stock | Warrants to purchase Common Stock |  |  |  |  |
Range of assumptions used to determine the fair value of warrants |  |  |  |  |
Measurement input | 1.10 |  | 1.10 |  | 1.16
Dividend yield | Warrants to purchase Common Stock |  |  |  |  |
Range of assumptions used to determine the fair value of warrants |  |  |  |  |
Measurement input | 0 |  | 0 |  | 0

X
- References No definition available. + Details
Name: | crdf_DerivativeFinancialInstrumentsLiabilityRollForward
Namespace Prefix: | crdf_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the estimated fair value of warrant. + References No definition available. + Details
Name: | crdf_EstimatedFairValueOfWarrant
Namespace Prefix: | crdf_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of warrants or rights outstanding. + References No definition available. + Details
Name: | us-gaap_ClassOfWarrantOrRightOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 + Details
Name: | us-gaap_DerivativeLiabilitiesNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_FairValueInputsQuantitativeInformationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_UnrealizedGainLossOnDerivatives
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_WarrantsAndRightsOutstandingMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |